Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes

by Nancy T.H. Colchester, David Allen, Haider A. Katifi, Tracy Burt, Robert N. Lown, Ashwin A. Pinto, and Andrew S. Duncombe

Haematologica 2020 [Epub ahead of print]


Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes

Authors:
Nancy TH Colchester, David Allen, Haider A Katifi, Tracy Burt, Robert N Lown, Ashwin A Pinto, and Andrew S Duncombe

1Department of Neurology, Wessex Neurological Centre, University Hospital Southampton, Southampton, UK
2Department of Neurophysiology, Wessex Neurological Centre, University Hospital Southampton
3Department of Haematology, University Hospital Southampton

Corresponding author:
Nancy TH Colchester
Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust,
Tremona Road, Southampton, Hampshire, UK, SO16 6YD
Email: Nancy.Colchester@uhs.nhs.uk
Tel: +44 (0) 773 0776 114

Word count:
1498 words. 1 table. 2 figures. No supplemental files.

Acknowledgements:

The authors would like to thank the patients for their engagement in the treatment and outcome monitoring. We also thank Rutaba Eshita, Mazen Sabah, Chinar Osman and Annamaria Kiss-Csenki, Consultant Neurologists at University Hospital Southampton (RE and CO) and at Hampshire Hospitals NHS Foundation Trust (MS and AK), for their work in performing the neurological assessments. We also thank Ian Galea, Associate Professor in Neurology at the University of Southampton and Consultant Neurologist, for his advice regarding the statistical analysis.
There is ongoing debate as to the optimum treatment for IgM paraproteinaemic neuropathy (PPN), with no treatment yet shown objectively to alter the long term natural history of slow neurological decline. We present a case series of 25 patients with IgM PPN treated, between August 2010 and October 2016, with standard R-CP (rituximab, cyclophosphamide, prednisolone) chemoimmunotherapy. This is the first report of detailed 2 year serological, neurological and neurophysiological outcome data in patients treated prospectively with this regimen. The treatment was well tolerated and produced significant improvement for at least 2 years in several neurological, electrophysiological and serological outcomes.

Peripheral neuropathy is a well-recognised complication of IgM paraproteinaemia, and occurs both in those with a monoclonal gammopathy of undetermined significance (MGUS), and in patients with an underlying lymphoproliferative disorder (LPD). Recent guidelines suggest that patients with renal or neurological complications of paraproteinaemia should be reclassified as having MGCS ("monoclonal gammopathy of clinical significance")\(^1\), to reflect the fact that they may merit treatment. In 50-60% of cases the M protein shows reactivity to a neural antigen known as myelin associated glycoprotein (MAG)\(^2\). There is accumulating evidence that the anti-CD20 monoclonal antibody, rituximab, benefits a proportion of patients with IgM paraproteinaemic neuropathy\(^3-6\). However there is insufficient evidence to assess the efficacy of rituximab alone compared with its use as part of a combined chemoimmunotherapy (CIT) regimen. International guidelines recommend that in patients with progressive disability due to anti-MAG neuropathy, immunosuppressive treatment should be considered as an alternative to rituximab monotherapy\(^7\). A retrospective analysis of 45 PPN patients treated with a variety of treatment protocols also suggests a role for CIT\(^8\). Finally, recent demonstration of a high prevalence of mutated myeloid differentiation factor 88 (MYD88), which is strongly associated with Waldenstrom's Macroglobulinaemia (WM), in patients with anti-MAG neuropathy supports the use of treatment regimens effective in WM\(^9\).

Here we report a large prospective case series of patients with progressive disability due to confirmed IgM paraproteinaemic neuropathy, treated with standard R-CP chemoimmunotherapy. R-CP is standard R-CVP, minus vincristine to avoid neurological toxicity. It is very similar to the DRC (dexamethasone, rituximab, cyclophosphamide) protocol\(^10\), used frequently in the treatment of WM, and similar to immunosuppressive protocols used in rheumatological disorders. All patients had IgM paraproteinaemia, fulfilling criteria either for WM or for MGCS, together with electrophysiological evidence of neuropathy. Comprehensive assessment was undertaken to establish a likely causal relationship between the IgM paraprotein and the neuropathy, and to exclude other conditions such as diabetic or vasculitic neuropathy.

33 patients have started treatment in total. We report results from 25 patients at 1 year and from 18 patients at 2 years (those who have reached these timepoints) (table 1).

Baseline investigations included bone marrow biopsy and CT body, as well as full standard haematology and biochemistry screen, serum protein electrophoresis, and anti-MAG antibody titres using an enzyme-linked immunosorbent assay (ELISA). MYD88 testing was not carried out as the patients presented here pre-dated the routine clinical use of this assay. Following fully informed
written consent, treatment comprised 6 cycles (every 21 days) of the following regimen: rituximab 375mg/m² intravenously and cyclophosphamide 750mg/m² intravenously on day 1; and prednisolone 50mg/m² orally on days 1 to 5. All patients completed the full treatment protocol and all received prophylaxis for at least 6 months post treatment to reduce treatment-related complications.

The treatment protocol was generally well tolerated. Complications were rare: 1 flu pneumonitis, 1 dental abscess, and 7 other minor complications, all of which resolved fully. This tolerance compares favourably with the larger rituximab monotherapy RCT, in which 8 serious adverse events occurred in 26 patients.

It has recently emerged that, out of 33 patients who have been treated in total, 3 patients have since developed IDH1 (isocitrate dehydrogenase) negative glioblastoma. 2 patients were anti-MAG positive with MGCS, 1 patient was anti-MAG negative with underlying WM. Given that the incidence of GBM is 3 in 100,000, this is concerning. At this stage it is unclear whether the GBM cases are (1) a random occurrence; (2) relate to the known association with WM and GBM; (3) reflect an unknown shared risk factor between IgM PPN and GBM, or (4) relate to the use of CIT in IgM PPN. The latter seems unlikely as firstly epidemiological studies of GBM show no link between immunosuppression and GBM incidence; and secondly this CIT regimen has been used widely in haematology and rheumatology for over 20 years, with no suggestion of a link with GBM.

The serology results in individual patients are shown in figure 1. At 2 years post treatment completion, paraprotein concentration fell compared to baseline in 17/18 (94%) patients (figure 1a). Median paraprotein concentration fell from 4.7g/L at baseline to 2.0 g/L at 2 years (p=0.000*). 12/13 anti-MAG positive patients showed a reduction in anti-MAG titre compared to baseline (figure 1b). Median anti-MAG titre at baseline was 38,956 Bühlmann titre units (BTU), falling to 14,783 BTU at 2 years (p=0.002*).

Neurological symptoms and disability were measured using the Overall Neuropathy Limitation Score (ONLS). A 1 point change in ONLS reflects a meaningful change in patient function, for example the difference between walking with or without an aid. Median ONLS showed a significant improvement from 3 at baseline to 2 at 1 year (p=0.006*), and to 1 at 2 years, (p=0.053). Motor function was quantified using the Medical Research Council (MRC) Sum Score of muscle power (range 0-80), in which for example a loss of just 1 point equates to the development of a partial footdrop. 18 patients (72%) had motor weakness at baseline, and 13 have 2 year follow-up data: MRC sum score in these patients showed a significant improvement in the median score (79) compared to baseline (76) (p= 0.031*), and 9/13 patients (69%) improved by at least 1 point. Sensory sum score reflects the extent of sensory loss in limbs: a change of 4 points reflects for example numbness receding from the knees to the ankles in both legs. Sensory Sum Score improved by at least 4 points in 9/18 (50%) patients compared to baseline. On direct questioning about their symptoms 2 years post-treatment, 65% of patients reported either improvement (8/17 patients) (47%) or stabilisation (3/17 patients) (18%).
Electrophysiology provides an objective, quantifiable measure of nerve function, which allows us to demonstrate whether the neuropathy is progressing, stable or improving. Our electrophysiological studies (see figure 2 for definitions) showed that the mean DML (distal motor latency) sum score improved from 10.7 ms at baseline to 9.1 ms at 2 years (p=0.005*) (figure 2a). SNAP (sensory nerve action potential) sum score also showed a trend to improvement, increasing from 11.7 uV to 15.7 uV at 2 years, (p=0.26) (figure 2b). Additional neurophysiology is presented in 8 off-protocol patients, as there is little in the literature regarding long term changes in neurophysiology in patients with IgM PPN. In these patients, both motor and sensory nerve conduction studies deteriorated over a 54 month period. The mean SNAP sum score significantly worsened from a baseline of 17.4 uV to 8.2 uV at 54 months (p=0.028*) (figure 2d). The mean DML sum score also deteriorated from a baseline mean of 12.9 ms to 15.1 ms over the same period (p=0.069) (figure 2c). The clinical importance of these findings is notable: we demonstrate that untreated patients show a progressive deterioration in neurophysiology which, despite not being directly comparable due to the differing follow-up times, is in contrast to those treated with this CIT regimen, who showed a significant improvement in motor response and a trend towards sensory improvement 2 years after treatment.

Our case series is not sufficiently large to study the factors which may predict individual patient responses by sub-group analysis. We plan to undertake further analysis at a later timepoint with a larger cohort of patients, in order to correlate neurological response with individual patient factors.

This is the first report in IgM paraproteinaemic neuropathy of the prospective use of a standardised CIT protocol with detailed outcome measures at 2 years post treatment. Although not a formal randomised comparison, our outcome data compare favourably with the rituximab monotherapy data from the literature. Based on more than 200 rituximab-treated patients, the average number of patients responding to treatment is 30-50% at timepoints of up to one year\(^6\), whereas our data illustrate improvements in 10/18 (55%) patients for ONLS, 9/13 patients (69%) for MRC sum score, 9/18 patients (50%) for sensory sum score and 11/17 patients (65%) for PROMS, at a longer timepoint of 2 years. However, despite the fact that CIT has been used safely in haemat-o-oncology and rheumatology for decades, this case series raises the possibility of an increased incidence of malignant primary CNS tumour in patients with IgM PPN treated with such protocols. It is important that other centres treating IgM PPN patients with CIT be vigilant for the occurrence of malignancy, particularly GBM. Further epidemiological study is needed to look at the incidence of GBM in other case series of IgM PPN, with or without treatment, and in patients treated with CIT for other indications.
REFERENCES


TABLE: PATIENT CHARACTERISTICS (25 patients)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at presentation</td>
<td>Mean 68 years (range 50-81)</td>
</tr>
</tbody>
</table>
| Gender                                              | Male: 20 (80%)  
Female: 5 (20%) |
| Duration of neuropathy symptoms prior to treatment | Median 5 years (range 1-20) |
| Haematological diagnosis                           | IgM MGCS: 16 (64%)  
WM: 8 (32%)  
CLL: 1 (4%) |
| Paraprotein concentration [g/L]                    | Median 4.7 (range 1.6-17.9) |
| Anti-MAG antibody status                            | Anti-MAG positive: 18 (72%) (>1,000 Bühlmann titre units)  
Anti-MAG negative: 7 (28%) |
| Clinical features                                   | (a) Defined neurological rating scales*:  
  - Median baseline ONLS: 3  
  - Motor weakness (MRC sum score <80): 18 (72%)  
  - Sensory sum score >10: 20 (80%)  
(b) Clinical opinion based on patient-reported symptoms and/or examination findings:  
  - Functional impairment affecting quality of life: 25 (100%)  
  - Distal limb numbness or paraesthesiae: 25 (100%)  
  - Sensory ataxia: 18 (72%) |
| Neurophysiology                                     | Demyelinating neuropathy: 19 (76%)  
Demyelinating / axonal neuropathy: 6 (24%) |
| Prior treatment for paraproteinaemic neuropathy     | None: 20 (80%)  
  Intravenous immunoglobulin (IVIG): 2 (8%)  
  Steroids: 2 (8%)  
  IVIG, cyclophosphamide and plasma exchange: 1 (4%) |

Abbreviations: MGCS = monoclonal gammopathy of clinical significance; WM = Waldenstrom's macroglobulinaemia; CLL = Chronic Lymphocytic Leukaemia; MAG = myelin-associated glycoprotein.

*Explanation of the neurological rating scales:
- **ONLS = Overall Neuropathy Limitation Score.** This reflects patients’ functional ability in the arms (range 0-5) and legs (range 0-7) (higher scores represent increasing levels of disability). A change of 1 point in the ONLS could for example reflect a change from walking with or without an aid.
- **MRC sum score:** this reflects muscle strength throughout the limbs. Note that in IgM paraproteinaemic neuropathy, the muscles involved are predominantly the distal leg muscles, and the MRC sum score in this condition would rarely be lower than 70. A drop of just 1 point to a score of 79/80 could for example reflect the development of focal weakness in the foot, and so is of clinical importance.
- **Sensory sum score:** normal sensation is equivalent to a score of 0, and worsening sensory impairment in 4 modalities (light touch, pinprick, vibration, and joint position sense) is represented by an increasing score, range 0-64. A change of 4 points could, for example, represent numbness receding from the knees to the ankles in both legs, leading to improved balance due to better proprioception.
R-CP in IgM paraproteinaemic neuropathy

FIGURE LEGENDS

Figure 1: Response of IgM paraprotein and anti-MAG titres to R-CP treatment

Figure 2: Motor and sensory electrophysiological changes 2 years post R-CP treatment compared with historical off-treatment group
DML mean sum score = mean of right median and ulnar nerve distal motor latencies.
Mean SNAP sum score = mean of right median, ulnar and radial nerve sensory nerve action potentials.
Error bars represent the standard deviation.
Abbreviations: DML = distal motor latency; SNAP = sensory nerve action potential; ms = milliseconds; µv = microvolts.
Figure 2a: Distal motor latency: mean sum scores at baseline, 12 and 24 months in protocol group (n=23 at 12 months and n=15 at 24 months)

Time in months post-treatment with RCP

Figure 2b: Sensory nerve action potentials: mean SNAP sum score at baseline, 12 and 24 months in protocol group (n=23 at 12 months and n=15 at 24 months)

Time in months post-treatment with RCP

Figure 2c: Distal motor latency: mean sum score trend in historical off-protocol group over a 54 month period (n=8)

Time in months

Figure 2d: Sensory nerve action potentials: mean SNAP sum score trend in historical off-protocol group over a 54 month period (n=8)

Time in months